Skip to content

Open Label Clinical Trial of Vitamin D in Children With Autism

Open Label Clinical Trial of Vitamin D Dosage Tolerability, and Effect on Behavioral Measures in Children With Autism

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01535508
Enrollment
10
Registered
2012-02-17
Start date
2012-02-29
Completion date
2015-12-31
Last updated
2019-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism, Vitamin D Deficiency

Brief summary

Primary: to investigate tolerability of interventional high dose Vitamin D3 supplementation, titrated to reach serum levels near the high end of the reference range (30-100 ng/ml), in vitamin D deficient pediatric Autism Spectrum Disorder (ASD) patients. The study will determine if initial safety and effect estimates predict that a double blind randomized control trial (RCT) with a larger set of patients will be worthwhile in the localization of this treatment aimed at improving the symptoms of ASDs. Exploratory: to determine efficacy of high dose D3 replacement for improvement in the core symptoms of autism, including sociability, eye contact, anger outbursts, stimming behavior, and sleep, as determined by parental and clinical evaluation scales.

Detailed description

data is still being collected

Interventions

DRUGLiquid Vitamin D

300 IU/Kg/day not to exceed 10,000 IU/day.

Sponsors

University of California, San Francisco
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
3 Years to 8 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of Autism from DSM-IV TR and ADOS * Moderate but less than severe on CGI-Severity scale * IQ \> 40 * ZRT 25(OH)D blood spot test \< 30 ng/ml * Age 3-8 years old

Exclusion criteria

* Developmental delays prior to 12 months of age * history of head trauma * seizure in the past year * bleeding disorder * history of kidney or liver disease * clinically significant low white blood cell count * PDD-NOS, Rett's syndrome, Childhood Disintegrative Disorder or Fragile X syndrome * current supplementation with Vitamin D, Vitamin A or cod-liver oil

Design outcomes

Primary

MeasureTime frameDescription
Clinical Global Impression Scale - Improvement (CGI-I)Baseline and 12 weeks from BaselineAssessment of global changes in severity of autistic symptoms. CGI-I scores formulated by the clinician based on parent interview of changes in the child's behavior and from direct clinical observation, where scores of 0 = no improvement,1 = minimally improved, 2 = much improved, and 3 = very much improved.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026